23andMe Holding Co. (ME) Return on Assets (ROA): -163.04%
Is 23andMe Holding Co.’s return on assets (ROA) high or low?
23andMe Holding Co.'s return on assets (ROA) of -163.04% is 96% below its 5-year average of -83.15%, near the low end of its 5-year range (-175.67%–-18.88%).
As of Wednesday, June 17, 2026. 5.31% above its 12-month average of -172.19%.
ME Return on Assets (ROA) Chart
ME Average Return on Assets (ROA) Chart
ME Current vs Average Return on Assets (ROA) Chart
ME Return on Assets (ROA) Metrics
RETURN ON ASSETS (ROA)
-163.04%
RETURN ON ASSETS (ROA) AVG TTM
-172.19%
RETURN ON ASSETS (ROA) AVG 3Y
-99.08%
RETURN ON ASSETS (ROA) AVG 5Y
-83.15%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+5.31%
CURRENT VS 3Y AVG
-64.55%
CURRENT VS 5Y AVG
-96.09%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
ME Competitors' Return on Assets (ROA)
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 23andMe Holding Co. (ME) | $15.31M | -163.04% | -172.19% | -99.08% | -83.15% |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.09B | -12.01% | -13.41% | -10.26% | -6.23% |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.02B | -0.58% | 11.88% | 0.12% | -6.73% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.84B | 1.72% | -6.26% | -11.14% | 1.46% |
| Tempus AI, Inc. (TEM)vs › | $8.82B | -14.19% | -43.49% | -42.71% | -41.26% |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.90B | -2.39% | -0.94% | 2.58% | 3.75% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -9.07% | -6.92% | -1.48% | 0.07% |
| Baxter International Inc. (BAX)vs › | $10.57B | -5.53% | -3.64% | -1.62% | 0.47% |
| Revvity, Inc. (RVTY)vs › | $11.29B | 2.01% | 2.19% | 1.89% | 3.83% |
| Align Technology, Inc. (ALGN)vs › | $12.86B | 6.81% | 6.68% | 6.69% | 12.75% |
Asset Efficiency
ROA
-163.0%
ROE
-721.8%
23andMe Holding Co. Return on Assets (ROA) Formula & Definition
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
23andMe Holding Co. Return on Assets (ROA) FAQ
- What is the return on assets (ROA) for 23andMe Holding Co. (ME)?
- The return on assets (ROA) for ME stock is -163.04%.
- Is 23andMe Holding Co.'s return on assets (ROA) high or low?
- 23andMe Holding Co.'s return on assets (ROA) of -163.04% is 96% below its 5-year average of -83.15%, near the low end of its 5-year range (-175.67%–-18.88%).
- What is the TTM average return on assets (ROA) for 23andMe Holding Co. (ME)?
- The TTM average return on assets (ROA) for ME stock is -172.19%.
- What is the 3Y average return on assets (ROA) for 23andMe Holding Co. (ME)?
- The 3Y average return on assets (ROA) for ME stock is -99.08%.
- What is the 5Y average return on assets (ROA) for 23andMe Holding Co. (ME)?
- The 5Y average return on assets (ROA) for ME stock is -83.15%.
23andMe Holding Co. Return on Assets (ROA) History
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-03-31 | -175.67% |
| 2024-03-31 | -168.71% |
| 2023-03-31 | -33.06% |
| 2022-03-31 | -18.88% |
| 2021-03-31 | -40.56% |
| 2020-03-31 | -62.00% |
| 2019-03-31 | -26.34% |
Related Metrics
About 23andMe Holding Co.
23andMe Holding Co. is a prominent direct-to-consumer genetic testing firm, structured around two primary business units: Consumer & Research Services and Therapeutics. Through its Consumer & Research Services division, the company provides individuals with a comprehensive suite of genetic reports, derived from a simple saliva sample collected via their proprietary kit. These reports offer insights into customers' genetic ancestral origins, predispositions to certain personal health risks, the likelihood of being a carrier for rare conditions that could be passed to offspring, and how their genetic makeup might influence responses to various medications. The Therapeutics segment is dedicated to pharmaceutical research and development, focusing on the discovery and advancement of novel treatments aimed at improving patient well-being across diverse medical fields, including oncology, respiratory, and cardiovascular diseases. This segment also engages in the out-licensing of intellectual property associated with identified drug targets that are progressing through clinical development. 23andMe maintains a strategic partnership with GlaxoSmithKline Intellectual Property (No.3) Limited, leveraging genetic insights to validate, develop, and ultimately commercialize new pharmaceutical products. Established in 2006, the company's corporate headquarters are situated in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Joseph Selsavage